IGF-1 LR3 vs CJC-1295: Direct IGF-1R Agonist vs Upstream GH-Axis Stimulant

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) and CJC-1295 (no DAC) both influence the growth hormone-IGF-1 axis, but they do so from opposite ends of the pathway through entirely different receptor systems. IGF-1 LR3 is a synthetic 83-amino acid analog of human IGF-1 that directly engages the IGF-1 receptor (IGF-1R) at peripheral target tissues while evading sequestration by IGF-binding proteins. CJC-1295 is a modified 29-amino acid GHRH analog that stimulates pituitary somatotrophs via GHRH receptors to release endogenous growth hormone, which then drives hepatic IGF-1 production through the normal GH-liver axis. The practical distinction is direct versus indirect IGF-1R signaling, with markedly different evidence depths: IGF-1 LR3 is a preclinical-only research reagent with no human trial data, while CJC-1295 has Phase 1/2 pharmacokinetic evidence in humans.

Key Differentiators at a Glance

Mechanism Side by Side

IGF-1 LR3: Direct IGFBP-Resistant IGF-1 Receptor Agonism

IGF-1 LR3 was engineered to solve a specific pharmacological problem: native exogenous IGF-1 is sequestered by circulating IGF-binding proteins (IGFBPs 1-6) within seconds of entering a serum-containing environment, leaving less than 1% as the free fraction available for receptor engagement. The LR3 modification achieves IGFBP evasion through two structural changes relative to native 70-amino acid IGF-1: a 13-residue N-terminal extension and a glutamic acid-to-arginine substitution at position 3. These changes reduce affinity for all six IGFBPs by approximately 1,000-fold while preserving full-affinity binding to IGF-1R (PMID 11735239).

Once administered and free of IGFBP sequestration, IGF-1 LR3 binds IGF-1R directly at muscle, liver, neural, cardiovascular, and other target tissues. Receptor engagement triggers trans-autophosphorylation of the tetrameric receptor tyrosine kinase, activating two main downstream branches. The PI3K/Akt/mTOR axis suppresses protein degradation (via FoxO1/FoxO3a phosphorylation, reducing MuRF1 and Atrogin-1 expression) and drives protein synthesis through mTORC1, S6K1, and 4E-BP1. The MAPK/ERK axis promotes cell proliferation, differentiation, and gene expression changes. Neither branch requires pituitary GH secretion or intact liver function to generate signal; IGF-1 LR3 is a direct peripheral agonist (PMID 32858949).

flowchart TD
    A["IGF-1 LR3\n(83 aa, exogenous)"] --> B["Evades IGFBP binding\n~1000x reduced affinity"]
    B --> C["Free peptide reaches\nperipheral target tissues"]
    C --> D["IGF-1R\n(receptor tyrosine kinase)"]
    D --> E["Trans-autophosphorylation\nIRS-1 recruitment"]
    E --> F["PI3K/Akt/mTOR axis"]
    E --> G["MAPK/ERK axis"]
    F --> F1["mTORC1 → S6K1 → protein synthesis"]
    F --> F2["FoxO1/3a phosphorylation\nreduces MuRF1, Atrogin-1"]
    G --> G1["Cell proliferation\ndifferentiation"]

    style A fill:#e07b39,color:#fff
    style D fill:#7b68ee,color:#fff
    style F fill:#2e8b57,color:#fff
    style G fill:#2e8b57,color:#fff

CJC-1295: DPP-IV-Resistant GHRH Receptor Agonism Driving Endogenous GH and IGF-1

CJC-1295 (no DAC, also called Mod GRF 1-29) acts upstream of the IGF-1 axis. Its primary target is the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, a G-protein-coupled receptor linked to Gs and adenylyl cyclase. Native GHRH is cleaved rapidly by dipeptidyl peptidase IV (DPP-IV) at the Ala-Asp bond at positions 1-2, yielding a plasma half-life of roughly 7 minutes. CJC-1295 carries four amino acid substitutions (at positions 2, 8, 15, and 27) that prevent DPP-IV cleavage, extending the effective subcutaneous bioactivity window to approximately 30 minutes while maintaining full GHRHR binding affinity (PMID 17635940).

GHRHR engagement activates Gs, raises intracellular cAMP, activates protein kinase A, and drives CREB phosphorylation, which upregulates GH1 gene transcription and triggers GH exocytosis from somatotroph granules. Released GH travels in circulation and binds GH receptors in the liver (and other tissues). Hepatic GHR signaling via JAK2-STAT5 drives IGF-1 gene transcription, and secreted IGF-1 enters circulation predominantly complexed to IGFBP-3 and acid-labile subunit (ALS). This endogenously produced IGF-1 then activates IGF-1R at peripheral tissues through normal physiological distribution. Somatostatin feedback remains intact, preserving the pulsatile GH release pattern and preventing continuous supraphysiological elevation.

flowchart TD
    A["CJC-1295 no DAC\n(29 aa, DPP-IV resistant)"] --> B["GHRHR on pituitary somatotrophs"]
    B --> C["Gs-coupled cAMP elevation\nPKA activation"]
    C --> D["CREB phosphorylation\nGH1 gene transcription"]
    D --> E["GH secretion\n(pulsatile; somatostatin feedback intact)"]
    E --> F["GH receptor in liver"]
    F --> G["JAK2-STAT5 signaling\nIGF-1 gene transcription"]
    G --> H["Circulating IGF-1\n(>99% IGFBP-bound)"]
    H --> I["IGF-1R at\nperipheral tissues"]
    I --> J["PI3K/Akt/mTOR\nMAPK/ERK downstream"]

    style A fill:#5b8dd9,color:#fff
    style B fill:#7b68ee,color:#fff
    style I fill:#7b68ee,color:#fff
    style J fill:#2e8b57,color:#fff

The end-point of CJC-1295 signaling (IGF-1R activation) is the same receptor that IGF-1 LR3 engages directly, but CJC-1295 reaches that endpoint through four sequential biological steps: pituitary GH release, hepatic IGF-1 synthesis, IGFBP complex formation, and IGFBP proteolysis to liberate free IGF-1 at target tissues.

Evidence Strength

IGF-1 LR3: Preclinical Only

The published literature on IGF-1 LR3 is extensive at the preclinical level and absent at the human clinical level. Skeletal muscle biology accounts for the largest fraction of publications: studies in myoblast and myotube cultures demonstrate 2- to 10-fold greater bioactivity than equimolar native IGF-1 in serum-containing media due solely to IGFBP evasion (PMID 15817840). Satellite cell proliferation work in bovine and porcine primary cultures has used IGF-1 LR3 as the receptor stimulus to characterize autocrine/paracrine IGF-1 signaling in regenerating muscle (PMID 24906928). Fetal development research in sheep models has used continuous IGF-1 LR3 infusion to demonstrate that IGF-1 is a direct fetal growth regulator; these studies have characterized organ-specific growth responses, pancreatic beta-cell feedback, and gastrointestinal ion transport (PMID 33427051, PMID 37114757, PMID 22227200). A 2025 mouse study (PMID 39610283) used intranasal IGF-1 LR3 to examine amyloid plaque remodeling in a transgenic Alzheimer’s model.

No completed human clinical trials of IGF-1 LR3 are registered on ClinicalTrials.gov (accessed April 2026). The compound is used as a research reagent in CHO bioreactor cell culture and as an anti-doping-relevant compound detected by mass spectrometry in sport samples (PMID 20675162). The closest approved clinical compound is mecasermin (Increlex), which is native recombinant human IGF-1 with a distinct sequence from IGF-1 LR3 (NDA 021839, approved for severe primary IGF-1 deficiency in children).

CJC-1295: Phase 1/2 Human Pharmacokinetic Data

CJC-1295 was evaluated in a ConjuChem-sponsored Phase 1/2 study (PMID 17635940) that enrolled healthy adults and patients with GH deficiency. A single subcutaneous injection of the DAC formulation (which attaches to albumin and extends half-life to approximately 7 days) produced mean GH increases of 2- to 10-fold lasting several days, with corresponding IGF-1 elevation. The no-DAC variant (Mod GRF 1-29) studied separately lacks the albumin-reactive maleimide group and has a considerably shorter effective window; controlled human trials specifically isolating the no-DAC pharmacokinetics are limited, with the existing evidence extrapolated from the DAC data and DPP-IV resistance mechanistic studies. No pivotal Phase 3 trials or regulatory submissions have been made for CJC-1295 in any formulation. Its upstream position in the GH-IGF-1 axis also means that efficacy depends on intact pituitary somatotroph function, liver GH receptor expression, and IGFBP metabolism, adding biological variability not present with direct IGF-1R agonism.

Safety Profile Differences

The safety considerations for IGF-1 LR3 and CJC-1295 differ substantially, partly because of their distinct receptor biology and partly because of the dramatic difference in available human data.

IGF-1 LR3 has no published human pharmacokinetics or safety data. Preclinical risk considerations derive from the biology of sustained, IGFBP-independent IGF-1R activation. IGF-1R is a recognized mitogenic pathway; its downstream PI3K/Akt signaling overlaps substantially with pathways mutated in cancer, and IGF-1R overexpression or hyperactivation is documented in multiple tumor types. Native rhIGF-1 (mecasermin) at therapeutic doses causes hypoglycemia (most clinically significant adverse effect, given IGF-1’s insulin-like receptor cross-reactivity), headache, papilledema, lipohypertrophy at injection sites, and tonsil/lymphoid tissue hypertrophy (NDA 021839 label data). IGF-1 LR3’s ~1,000-fold lower insulin receptor cross-reactivity (relative to IGFBP resistance) may modulate hypoglycemia risk differently from native IGF-1, but no human data exists to characterize this. The compound appears on the WADA prohibited list, and anti-doping detection methods have been validated using mass spectrometry (PMID 20675162).

CJC-1295 operates upstream and physiologically: because it stimulates endogenous GH release rather than bypassing the liver and peripheral IGFBP system, the magnitude of IGF-1R signaling generated is constrained by pituitary GH secretory capacity and normal IGFBP kinetics. The Phase 1/2 study (PMID 17635940) identified injection-site reactions, transient facial flushing, and mild headache as the most common adverse effects. Water retention and paresthesia consistent with GH elevation appear in the broader research-use literature. Somatostatin feedback is intact, limiting the ceiling on GH elevation and providing a degree of physiological autoregulation absent with direct IGF-1R agonism. The 30-minute effective half-life of the no-DAC version means each injection’s effect is time-limited, reducing sustained IGF-1R exposure relative to a long-acting IGF-1 analog.

Neither compound is appropriate for populations with active malignancy, given IGF-1R’s role in tumor proliferation. IGF-1 LR3’s direct receptor action at peripheral tissues creates a more direct on-target risk in that context than CJC-1295’s indirect, IGFBP-buffered pathway.

Practical Research-Context Differences

Level of axis intervention. IGF-1 LR3 is a peripheral effector; its activity in isolated cell cultures, tissue preparations, or animal models does not require the brain, pituitary, or liver to be intact or functional. CJC-1295 requires the entire GH-IGF-1 axis to be functional from pituitary through liver to generate an IGF-1 response. This makes IGF-1 LR3 more useful in studies designed to isolate downstream IGF-1R signaling, and CJC-1295 more useful in studies examining integrated axis regulation.

Serum-free culture use. IGF-1 LR3 is a standard supplement in defined serum-free media for bioreactor cell culture, particularly CHO cells used in recombinant protein manufacture. CJC-1295 is not used in this context; pituitary cells are absent in bioreactor systems.

Physiological relevance of GH pulsatility. CJC-1295 preserves the pulsatile GH secretion pattern mediated by somatostatin feedback, which is considered physiologically relevant for many research questions about GH axis biology. IGF-1 LR3 creates sustained, non-pulsatile receptor occupancy; there is no equivalent of somatostatin feedback governing IGF-1R occupancy when an exogenous IGFBP-resistant ligand is present.

Fetal and developmental models. The bulk of in vivo IGF-1 LR3 infusion work comes from sheep fetal physiology research, where continuous intra-fetal infusion allows controlled IGF-1R activation independent of fetal IGFBP status. CJC-1295 would not be appropriate for this use case: fetal pituitary function and axis maturity would confound results and the pituitary-dependent signaling chain is not reliably intact in early fetal development.

Reproducibility and reagent standardization. Recombinant IGF-1 LR3 expressed in E. coli is commercially available from multiple validated research reagent suppliers with established reference standards. CJC-1295 is available through research peptide suppliers but lacks the equivalent standardization infrastructure, which can introduce batch-to-batch variability in cross-laboratory research settings.

When Researchers Choose IGF-1 LR3

IGF-1 LR3 is the compound of choice when the research question requires direct, IGFBP-independent IGF-1R activation at the level of target tissues, without the biological noise introduced by the GH-liver axis. It is appropriate for:

• Cell culture and ex vivo experiments where pituitary GH signaling is absent and a potent IGF-1R stimulus is needed that will not be neutralized by secreted IGFBPs in serum-containing media.
• In vivo studies in fetal or neonatal animal models where the GH-pituitary axis is immature or not intact, and direct IGF-1R stimulation is the target.
• Pharmacological validation experiments requiring a positive control for PI3K/Akt/mTOR or MAPK/ERK pathway activation downstream of IGF-1R.
• Cancer biology studies characterizing IGF-1R-mediated signaling in tumor cell lines, where IGFBP expression by tumor cells would neutralize native IGF-1.
• Anti-doping and detection research, where IGF-1 LR3’s distinct sequence from native IGF-1 is a detection target for mass spectrometry method development.

When Researchers Choose CJC-1295 (no DAC)

CJC-1295 is selected when the research question involves the integrated GH secretory axis, rather than isolated peripheral IGF-1R signaling. It is appropriate for:

• Studies examining pulsatile GH secretion, somatostatin feedback dynamics, or somatotroph cell biology in vivo.
• Research into the regulation of endogenous IGF-1 production through the GH-liver JAK2-STAT5 pathway.
• Combination studies with GHRPs (most commonly Ipamorelin) investigating the dual-pathway (GHRH plus ghrelin receptor) mechanism of GH release amplification.
• Pharmacokinetic and pharmacodynamic characterization of DPP-IV-resistant GHRH analogs, building on the Phase 1/2 data from PMID 17635940.
• Research contexts where preserving physiological GH pulsatility and the IGFBP buffer system is important to the study design.

Closing

IGF-1 LR3 and CJC-1295 are not competing compounds in the conventional sense: they do not target the same receptor, and they occupy fundamentally different positions in the GH-IGF-1 signaling hierarchy. IGF-1 LR3 operates at the receptor level in peripheral tissues with direct, IGFBP-resistant IGF-1R agonism; CJC-1295 operates four biological steps upstream by stimulating pituitary GH release through GHRHR. Selecting between them is therefore not a question of potency or preference within one pathway; it is a question of where in the axis the research question is focused.

Neither compound is approved for human therapeutic use. IGF-1 LR3 has no human evidence base. CJC-1295 has limited Phase 1/2 data, without a path to regulatory approval. Investigators using either compound in animal or cell models should consult their institution’s research compliance requirements, and clinicians supervising GH-axis research should monitor IGF-1, fasting glucose, and relevant metabolic markers.

For deeper context on each compound, see the full research hub pages:

• IGF-1 LR3 Research Hub
• CJC-1295 Research Hub

See also

Individual research hubs:

• IGF-1 LR3 research
• CJC-1295 research

Shared pathway context:

• IGF-1 / JAK2-STAT5 Signaling Axis

Related comparisons:

• IGF-1 LR3 vs Sermorelin
• BPC-157 vs CJC-1295
• CJC-1295 vs Cjc 1295 Dac